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The ampulla of Vater is a complex cellular environ-
ment from which adenocarcinomas arise to form a
group of histopathologically heterogenous tumors.
To evaluate the molecular features of these tumors,
98 ampullary adenocarcinomas were evaluated and
compared to 44 distal bile duct and 18 duodenal ad-
enocarcinomas. Genomic analyses revealed muta-
tions in the WNT signaling pathway among half ofCthe patients and in all three adenocarcinomas irre-
spective of their origin and histological morphology.
These tumors were characterized by a high fre-
quency of inactivating mutations of ELF3, a high
rate of microsatellite instability, and common focal
deletions and amplifications, suggesting common
attributes in the molecular pathogenesis are at play
in these tumors. The high frequency ofWNT pathway
activating mutation, coupled with small-molecule in-
hibitors of b-catenin in clinical trials, suggests futureell Reports 14, 907–919, February 2, 2016 ª2016 The Authors 907
treatment decisions for these patientsmay be guided
by genomic analysis.INTRODUCTION
Though the pancreas, bile duct, and intestinal duodenum share
common embryologic origins in the ventral endoderm, the
adenocarcinomas arising in this region presumably originate
from different epithelial cellular constituents present at the site
(Zaret and Grompe, 2008). These tumors have been described
in many different ways: intra-ampullary, periampullary, intra-
ampullary papillary-tubular neoplasm, ampullary/ductal, periam-
pullary-duodenal, and ampullary/not otherwise specified. The tu-
mors clearly separated from the ampulla of Vater and localized in
the bile duct, duodenum, or pancreatic duct have been identified
as distal cholangiocarcinomas or distal bile duct (CAC), duodenal
(DUOAC), or pancreatic ductal (PDAC) adenocarcinomas.
As recommended in the AJCC seventh edition 2009 staging
system (Edge et al., 2009), the current subtype classification of
ampullary adenocarcinoma (AMPAC) is based on the anatomical
location from which the tumor is thought to arise (Edge et al.,
2009), sometimes supplemented by histopathology and expres-
sion of differential markers (Adsay et al., 2012; Chang et al.,
2013; Ehehalt et al., 2011; Morini et al., 2013). This classification
is subjective and prone to inter-observer variability and can
significantly impact treatment selection and therapeutic devel-
opment (Amptoulach et al., 2011; Heinrich and Clavien, 2010;
Romiti et al., 2012; Westgaard et al., 2013). Current treatment
approaches do not distinguish patients based on subtypes, yet
tumors may arise from at least the three epithelia that converge
at that site, and somemay arise from the ampulla itself, where lit-
tle is known of the specialized epithelium that may be present.
Malignancies that arise from different cellular origins often
have vastly differing sensitivities to therapeutics. Post hoc ana-
lyses of clinical trials using histopathological criteria have not
discerned such a difference and likely represent the inaccuracy
of such a classifier. However, as most therapeutic development
is focused on agents that target specific molecular mechanisms,
a molecular characterization that would allow selection of pa-
tients for specific therapies would facilitate therapeutic develop-
ment with the aim of improving outcomes and alleviate the
impact of an inaccurate subjective classification.
For this study, we have assembled a large cohort of AMPAC
with nearby DUOAC and CAC for comparison. We show that
tumors from the duodenum, ampulla of Vater, and distal bile
duct exhibit a common spectrum of features irrespective of
their morphology, marker expression, and cellular origin. Here,
we use the term ‘‘periampullary tumors’’ in this study to refer to
the three tumor types of AMPAC, DUOAC, and CAC collectively,
as defined by the AJCC seventh edition 2009 staging system
(Edge et al., 2009), excluding cases that clearly arise from the
pancreas (pancreatic adenocarcinoma [PDAC]).RESULTS
In order to develop a molecular taxonomy for periampullary can-
cers and define subtypes with clinical relevance, we performed908 Cell Reports 14, 907–919, February 2, 2016 ª2016 The Authorsexome sequencing and copy-number analysis of 160 cancers
arising in the periampullary region, 62 of these clearly arising
from either the bile duct (n = 44) or the duodenum (n = 18) and
98 for which the epithelium of origin could not be clearly defined
morphologically (AMPAC). Mutations were validated by deep
and ultra-deep sequencing on a limited target region consisting
of 71 recurrently mutated genes. RNA sequencing (RNA-seq)
was performed on 30 patients: a 28-patient subset of the 98
ampullary tumors and a two-patient subset of the 18 duodenal
tumors.
Clinical Characteristics and Subtyping
The clinical characteristics of our patient cohort are described in
Table S1A. In this study, the anatomical primary site of origin of
all tumors was defined using the AJCC seventh edition 2009
staging system (Edge et al., 2009). In addition, the tumors were
also classified independently by cellular morphology and immu-
nohistochemistry (IHC) staining (see Experimental Procedures)
into intestinal, pancreatobiliary, or mixed subtypes (Table S1B).
Since treatment may be determined based on subtypes defined
by the combination of morphology and IHC even if these mea-
sures are somewhat subjective, it was an important objective
of our study to assess the reliability and meaning of these sub-
types. Subtyping according to IHC, the AMPAC tumors were
51% pancreatobiliary and 34% intestinal, with the remainder
mixed. CAC was dominated by the pancreatobiliary subtype,
86% as expected; however, 11% of CAC exhibited an intestinal
phenotype. In DUOAC, the intestinal subtype was 44%, with
22% pancreatobiliary and the remainder mixed.
By histological morphology, a smaller proportion of each
tumor type was classified as pancreatobiliary (AMPAC, 37%;
CAC, 77%; and DUOAC, 6%). The two methods of classifica-
tion yielded concordant subtypes only 62% of the time for
AMPAC tumors, 77% of the time in CAC, and 53% of the time
in DUOAC. Although the two methods often disagreed, all three
tumor types included in their numbers concordant cases of
all three subtypes. Thus, tumors originating in each organ site
in the periampullary region may be classified as any of the
three subtypes, though this classification system is rarely
applied to DUOAC or CAC tumors. These tumors were analyzed
by genomic methods to further characterize their molecular
properties.
Mutation Analysis
Exomes were sequenced to an average of 120-fold coverage re-
sulting in 28,795 mutations across 152 patients. Eight additional
patients were sequenced with targeted custom sequencing
and were included in the study (see Supplemental Experimental
Procedures, ‘‘Sequencing design and Mutation analysis,’’ and
Tables S1C–S1E). Microsatellite instable phenotypes were
observed in 12 patients representing each organ cohort (Fig-
ure 1), accounting for 18,572 of the whole-exome sequencing
(WES) discovery set. Using a method we developed based on
the enzyme slippage of the homopolymer region (E.S., unpub-
lished data), we identified two other patients among the targeted
sequencing set (Figure S1A).
Excluding microsatellite instable (MSI) tumors and correc-
ting for tumor purity, the median mutation rate did not vary
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Figure 1. Mutation Frequencies and MSI
Characteristics
(A) Mutation frequencies for all patients by
anatomical site (D, DUOAC; A, AMPAC; C, CAC)
and subtype (I, intestinal; M, mixed; PB, pan-
creatobiliary). Black dots, microsatellite stable
(MSS); red dots, microsatellite instable (MSI).
(B) Germline mutations in MMR gene associated
with Lynch syndrome were detected in 66% of the
MSI samples. Survival (m) is in months; black tile,
patient died of disease; white tiles, patient alive;
Lynch Mutation Freq, frequency each gene is
observed in Lynch syndrome patients; blue tiles,
missense mutations; green, frameshift mutations;
red, nonsense mutations; ‘‘L’’ = known Lynch
syndrome mutation; ‘‘d’’ deleterious mutation by
PolyPhen2.
(C) Kaplan-Meier plot for survival based on MSI
status in AMPAC (log rank p = 0.04, n = 96).
(D) Kaplan-Meier plot for survival based on MSI
status in all periampullary tumors (p = 0.0028,
n = 160).
See also Figures S1A–S1C and Tables S1A–S1E.significantly across the AMPAC, CAC, and DUOAC (3.8, 4.6, and
4.7 per Mb, respectively) but was clearly distinct from the MSI
mutation rate (68, 127, and 108 per Mb, respectively) (Figures
1A, S1B, and S1C). Two-thirds of the hypermutated WES sam-
ples had germline mutation in genes associated with Lynch syn-
drome. Interestingly, PMS2, a gene that accounts for less than
5% of Lynch syndrome patients overall (Thompson et al.,
2004) (OMIM #600259), was mutated in one half of our MSI pa-
tients (Figure 1B). Although MSI was more common in DUOAC
than CAC patients, every morphologic category harbored at
least one PMS2 germline mutation in this study. Leaving aside
germline contribution, the overall frequency of MSI in AMPAC
was 3%. MSI appeared to confer a survival advantage in
AMPAC, as it does in other gastrointestinal (GI) cancers, as all
six AMPAC patients were alive ranging from 2 to 8 years after
diagnosis (p = 0.04 with a lack of negative event) (Figure 1C).
Taking all three anatomical sites into consideration, MSI have
better survival, p < 0.0021 (Figure 1D).
Non-negative matrix factorization was used to evaluate the
mutation signatures associated with periampullary tumors. We
identified five prominent signatures, out of 21 observed (Figures
2A, S2A, and S2B; Table S2). The most common signature was
C > T at CpG islands (#6). Indeed, this signature is most common
across all tumor types. A few CAC and AMPAC tumors had a
strong T > G, > C signature (#7) associated with the digestive
track tumors and consistent with DNA damage and exposure
to arsenic (Martinez et al., 2013). A C > G signature (#4) charac-
teristic of DNA damage by APOBEC enzymes was also present
in a few patients (Roberts et al., 2013).Cell Reports 14, 907–919We observed signature #1 at greater
than 20% of the total signature in 9.6%
of our entire tumor set (6% AMPAC and
21% CAC). Signature #1 is characterized
by AC, AT > AN and is enriched in non-
transcribed regions of the genome insamples from several cancer types (PDAC, medulloblastoma,
breast tumor, AML, and CLL). However, signature #1 was also
observed in the coding region of 18 out of 486 hepatocellular car-
cinoma (4%) and 31 out of 450 colorectal carcinoma (CRC) (7%)
(Lawrence et al., 2013; Totoki et al., 2014; K.R.C., unpublished
data). Whereas none of the known signatures have yet been
associated with a difference in outcome, signature #1 was asso-
ciated with poor outcomes in our study set (multivariate Cox pro-
portional hazards p = 0.02) (Figure 2B).
The analysis of the periampullary tumors, excluding MSI pa-
tients, revealed 19 genes mutated significantly above back-
groundusingMutSig-CV (Lawrence et al., 2013) (Figure 3A; Table
S3A). Considering the ratio of inactivating tomissensemutations,
an additional three genes were brought in to the significantly
mutated gene list (Table S3B) including PBRM1, RECQL4, and
KDM6A. Gene expression data confirmed that the variants
harboring missensemutation in the driver genes were expressed
between 85% and 88% of the time (Table S3C).
Most interestingly, ELF3 a transcriptional regulator of TGFBR2
was mutated in 10.6% of the periampullary tumors with predom-
inantly inactivating frameshift or nonsense mutations (Figure 3B).
This mutation frequency is three times higher than in any other
cancer (Table S3D) (Cerami et al., 2012; Gao et al., 2013; Law-
rence et al., 2014) (http://www.cBioPortal.org). In agreement
with our finding, ELF3mutations were found in 9.5% of extrahe-
pathic CAC in a recent study of 74 samples with four inactivating
mutations out of seven (Nakamura et al., 2015). ELF3 mutation
occurred 71%of the timewithWNTpathwaymutations in all three
periampullary groups (Figure S3A). (chi-square test, p = 0.02)., February 2, 2016 ª2016 The Authors 909
AB
Figure 2. Mutation Signature in Periampullary Tumors
(A) Heatmap of five dominant mutation signatures from NMF analysis of mutation spectrum for each subject. Intensity indicates the proportion of mutations for
that subject attributed to the indicated signature. Subjects are sorted first by signature 1, then signature 6 from the highest to the lowest value. Only signatures
with high penetrance are shown.
(B) Kaplan-Meier curve of survival in this cohort stratified by signature 1 levels (high, red line: signature 1 component >10% of all mutations; low, black line:
otherwise, multivariate Cox proportional hazards p = 0.001).
See also Figures S2A and S2B and Table S2.Considering the 44 CAC alone, four genes were significantly
mutated in this cancer: TP53, KRAS, SMAD4, and CDKN2A
with the highest mutation incidence in TP53. Whereas intrahe-
patic CAC tumors frequently harbor BAP1, IDH1, and IDH2
(Nakamura et al., 2015), these were absent with the exception
of a single IDH1 hotspot mutation in the periampullary CAC.
This is in agreement with Nakamura et al. (2015), where no
IDH1 mutations could be detected among 74 extrahepatic tu-
mors (compared to a 5% mutation rate in intrahepatic tumor)
and a less than 3% BAP1 mutation rate was found in extrahe-910 Cell Reports 14, 907–919, February 2, 2016 ª2016 The Authorspatic tumors (compared to a 12.4%mutation rate in intrahepatic
tumor).
Alteration of Key Signaling Pathways
The significantlymutated genes defined five pathways in periam-
pullary tumors: TP53/cell division, RAS/PI3K, WNT, TGF-b,
and chromatin remodeling pathways. We combined the point
mutations and copy-number alterations (CNA) changes at
the gene level within these five pathways to assess the impact
of these pathways among the three anatomical sites (Figures
Figure 3. Significantly Mutated Genes in
Non-MSI Periampullary Tumors
(A) Significantly mutated genes are displayed by
FDR value (MutSigCV). Genes with FDR < 0.1 are
located in the left panel, genes with FDR > 0.1 but
significantly inactivated are in the middle panel,
and genes slightly under the significant threshold
of the significantly mutated gene (SMG) list are in
the right panel. The amount of samples for each
tumor type is stacked.
(B) ELF3 inactivating mutations were distributed
along the entire gene characteristic of a tumor
suppressor (q < 1.6 3 1011). All the mutations
found in the study are represented in the figure,
each mutation being found in one patient.
See also Tables S3A and 3B–S3D.4A and 4B). The similarities and differences in gene mutations
per tumor types and subtypes are illustrated in Figures S3A
and S3B.
TheWNT pathway was mutated in 46% of patients overall but
was clearly differentially mutated across the three tumor types,
being more frequently mutated in DUOAC (72%) than in AMPAC
(49%) or CAC (30%) (chi-square p < 0.05) (Tables S4A and S4B).
This predominance of WNT pathway mutation in DUOAC was
due mainly to more frequent mutations of APC and SOX9.
Whereas the TP53, RAS, TGF-b signaling and chromatin remod-
eling pathways are deregulated in many tumor types, the WNT
pathway deregulation is reported only in gastrointestinal tumors
(Biankin et al., 2012; Cancer Genome Atlas, 2012). We reasoned
that grouping the patients by our histological classification might
enrichWNTmutation in the intestinal subtype relative to the pan-
creatobiliary subtype. As expected, the intestinal subtype had
67% WNT pathway alterations compared to pancreatobiliary
with 30% WNT alterations, very close to the WNT frequency
based on anatomical site (Figures 4B, S3A, and S3B; Tables
S4A and S4B). Although we observe a gradient ofWNT pathway
disruption in tumors as their anatomical site moves away from
the GI tract,WNT mutation is still frequent in CAC, or ‘‘pancrea-
tobiliary’’ subtype tumors.
TGFBR2 was also more frequently mutated in DUOAC than
AMPAC and CAC, but this may have been secondary to MSI,
which was in higher proportion in DUOAC. TGFBR2 harbors an
A homopolymer run of eight bases that is a frequent target ofCell Reports 14, 907–919mutation in MSI patients, and 5 of the 12
TGFBR2 mutations were at this site.
Interestingly, SMAD4, a gene frequently
mutated in PDAC, was the most
commonly mutated gene of the TGF-b
pathway in AMPAC and CAC, the tissue
sites in closest proximity to the pancreas.
Mutant KRAS was the major RAS
signaling oncogene in all three tumor
types. Overall, the RTK/RAS/PI3K path-
way was activated in all periampullary pa-
tients at a statistically similar rate ranging
from 84% to 94% among the three tumor
types (Tables S4A and S4B).Alterations in the SWI/SNF chromatin remodeling pathway
were observed most frequently in ARID1A and ARID2. Overall,
mutations in the SWI/SNF complex were equally frequent in
the three tumor types.
Pathway Mutation Correlates with Disease Outcome
Multivariate analyses on the periampullary tumors as a group
showed mutations in the TGF-b pathway are associated with
better overall survival (multivariate Cox proportional hazard
p = 0.0059, HR = 0.42) independent of stage, gender, subtype,
and MSI status (multivariate Cox proportional hazard p =
0.029). Mutations in the PI3K pathway were also associated
with better overall survival (multivariate-Cox proportional haz-
ards p = 0.036, HR = 0.43) (Figure S3C). Mutations in TP53,
KRAS, WNT, and chromatin remodeling pathways showed no
significant association with outcomes in multivariate modeling.
Interestingly, TGF-b pathway mutations were also negatively
associated with mutation signature 1 (multivariate ANOVA p =
0.02), possibly explaining the association with outcomes. How-
ever, the contribution of signature 1 to outcomes was still signif-
icant when considering TGF-b pathway mutations in the model,
indicating that these two effects are not entirely redundant.
RNA Expression
RNA expression was analyzed in 28 AMPAC and 2 DUOAC. Due
to the high frequency of mutation inWNT and the current devel-
opment of therapeutic agents targeting b-catenin, we evaluated, February 2, 2016 ª2016 The Authors 911
Figure 4. Major Altered Pathways in Periampullary Tumors
(A) Frequency of changes defined by somatic mutations or copy-number loss or gain is expressed as a percentage of cases for each gene. Inactivation (blue) or
activation (red) is graded in intensity by percent of patients affected.
(B) Genetic alterations in the significantly mutated genes grouped by pathway are illustrated for each patient. NoteWNT and PI3K signaling pathways could be
found in the three tumor types and in each of their subtypes, including the pancreatobiliary subtype.
See also Figures S3A and S3B, wherein mutations in each gene are grouped by tumor type and subtype, and Figure S3C and Tables S4A and S4B.
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Figure 5. Relative RNA Expression of WNT
Antagonist, Agonist, and Target Genes
Tumors were split between those with and without
WNT canonical pathway mutations as shown in
the mutation panel. The level of RNA expression
for each gene can be visualized in the heat map
and the average expression of all the genes is
summarized in the lower panel. See also Figure S4
for fusions.the expression data using a previously developedWNT signature
that included WNT antagonist, WNT agonist, and WNT target
genes (Donehower et al., 2013). An increase in expression in
these three gene groups as a result of theWNT pathway dereg-
ulation was noticed in colorectal cancer (Donehower et al.,
2013). This could be explained by the fact that CTNNB1 activa-
tion resulted in an increased expression of targeted genes and
the unrestricted WNT signaling set up a negative feedback
loop of the WNT antagonist genes attempting to shut down
signaling. In this study, we divided the patients into WNT
mutated and those without (Figure 5, mutation panel). We then
looked at the relative RNA expression in the two tumor groups
forWNT antagonists,WNT agonists, andWNT targets (Figure 5,
middle panel). The tumors with WNT mutations trend signifi-
cantly toward higher overall WNT gene expression (p < 0.001)
(Figure 5, lower panel). The WNT gene expression profile was
also increased in some of the WNT non-mutated patients, indi-
cating that some other mechanism affecting the WNT pathway
might be at play.
Fusion analysis identified two noticeable non-recurrent fu-
sions: SLC45A3-ELK4 used as a prognosis marker in prostateCell Reports 14, 907–919cancer, where its expression is elevated
(Kumar-Sinha et al., 2012; Ren et al.,
2014), and a LINE-MET fusion in a patient
without any KRAS or TP53 driving
mutations and a high MET expression
(Figure S4; Table S5). LINE element
insertions are found in PDAC, colon,
hepatocellular, esophageal, and lung
carcinoma (Paterson et al., 2015; Rodic
et al., 2015).
Copy-Number Alteration
The majority of CNAs involved entire
chromosomes or chromosome arms as
opposed to focal events, which are com-
mon in gastrointestinal tumors. Arm-level
deletions outnumbered amplifications
across all tumors (Figure 6A). The three
tumor types shared four arm-level ampli-
fications and nine arm-level deletions.
AMPAC shared amplification of 1q and
deletion of 1p and 8p CAC (Table S6A).
AMPAC shared no events specifically
with DUOAC, making AMPAC marginally
more similar to CAC in its CNA pattern.
AMPAC also had two unique amplica-tions on 5p and 6p, whereas 3q amplification was unique to
CAC, and 6p was unique to DUOAC.
A combined GISTIC analysis revealed as expected a focal
deletion of 9p23.1, involving CDKN2A (Table S6B). A focal
deletion in chromosome 9 removed the promotor and 50 end of
KDM4C (Figure 6B). Although present in every tumor type, it
was only statistically significant in AMPAC (Table S6B). This
deletion resulted in a significant decrease in expression of
KDM4C as well as the upstream UHRF2 (Figure 6B, inserts).
Interestingly, overexpression of both genes has been associated
with a pro-growth effect on colon cancer cells (KDM4C) and a
much lower disease-free survival and overall survival in patients
with colon cancer (UHRF2) (Lu et al., 2014; Kim et al., 2014).
KDM4C forms also complexes with b-catenin (Kim et al., 2014;
Yamamoto et al., 2013).
DISCUSSION
This study compares the genetic constitution of ampullary can-
cer with two nearby tumor types with pathologic classification.
Historically, ampullary cancers have been classified as intestinal, February 2, 2016 ª2016 The Authors 913
Figure 6. Copy-Number Alteration
(A) Nexus GISTIC analysis of copy-number alteration by anatomical site. Upper blue panel shows copy-number gains and the lower red panel shows copy-
number losses for each tumor type. Blue arrows demark changes characteristic of a given anatomical site.
(legend continued on next page)
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or pancreatobiliary subtypes based on immunohistochemistry
and/or cellular morphology. The genomic analysis mirrored
these results by the finding that some ampullary tumors exhibit
properties of intestinal tumors such as microsatellite instability,
ELF3 mutation, and disruption of WNT signaling.
We found that the classification approaches of the three peri-
ampullary tumors are often discordant with one another. No
unique molecular characteristics were specifically associated
with one tumor subtype or one tumor type. Interestingly patients
from each tumor type and subtype exhibited alterations in WNT
pathway genes, including nearly one-fourth of the CAC tumors
and one-fourth of the pancreatobiliary tumors. Other studies
using subtype classification different from ours report WNT
pathway mutations in AMPAC pancreatobiliary (PB) subtype
(Achille et al., 1996; Hechtman et al., 2015). Transcriptional
changes in AMPAC tumors in WNT signaling genes was
increased, as expected, in tumors with WNT mutation, reinforc-
ing a molecular dichotomy. With half of the patients across the
three tumor types harboring WNT mutation, this could impact
greatly the choice of treatment since several WNT pathway tar-
geted therapies are in development. Ampullary, duodenal and
distal bile duct adenocarcinoma could be regarded as a WNT
± entity from the perspective of treatment. Thus, the molecular
data suggest that clinical testing forWNT signaling status might
be beneficial to patients in the near future, making this a stepping
stone to personalized medicine.
The identification of ELF3 as a significantly mutated gene with
an inactivating mutation pattern is also of interest. It was re-
ported at lower frequency in bladder and biliary tract cancers,
but not in any other cancer so far. ELF3 encodes an ETS-domain
transcription factor. By interacting with promoter regions, ELF3
is implicated in the regulation of several genes during epithelial
cell differentiation (Oliver et al., 2012). One of the genes transac-
tivated by ELF3 is TGFBR2, a prime initiator of TGF-b signaling, a
pathway with a dual role in tumorigenesis, suppressing tumor
progression at early stages but enhancing invasion and metas-
tasis at later stages (Roberts and Wakefield, 2003). The tumor-
suppressor antiproliferative function of ELF3 was previously
noted in studies on colorectal, prostate, and oral squamous can-
cer cells (Iwai et al., 2008; Lee et al., 2003, 2008; Shatnawi et al.,
2014) andmore recently in biliary tract cancer cell line (Nakamura
et al., 2015). Such studies showed that ELF3 directly binds to the
promoter region of EGR1 (Lee et al., 2008) and TGFBR2 (Lee
et al., 2003), increasing the transcription of these two tumor
suppressor genes in CRC, whereas ELF3 binding to androgen
receptor (AR) (Shatnawi et al., 2014) and matrix metalloprotei-
nase-9 (MMP9) (Iwai et al., 2008) promoters suppressed the
transcriptional activity of these tumor growth- and invasive-
ness-promoting genes in prostate and squamous cancers,
respectively. However, recent observations also suggested an
oncogenic functional role in CRC development when ELF3 is
amplified, and its upregulated expression correlated with cancer
progression and decreased patient survival (Wang et al., 2014).(B) Focal deletion in the promotor region and at the 50 end of KMD4C impacts its an
(Integrative Genomics Viewer, Broad Institute). Deletions are in blue, and amplifica
groups: samples with (1) or without (2) focal deletion. The color ladder on the righ
See also Tables S6A and S6B.
CA WNT-independent CTNNB1 transactivation facilitating tumor
development was also reported (Wang et al., 2014). Such dual
function has also been observed in breast and prostate cancer
(Longoni et al., 2013; Oliver et al., 2012; Shatnawi et al., 2014).
It could be argued that when ELF3 inactivation occurs early in tu-
mor development, it provides a moderate growth advantage by
suppressing TGF-b signaling. The fact that we found ELF3muta-
tion in a duodenal adenoma with intraepithelial neoplasia and
dysplasia components (DUOAC 707) and that 75%of the tumors
with ELF3mutation were lower-grade tumors (stage I or II) could
support this hypothesis. The ELF3 functional switch might
depend on tumor stage and expression of other factors and/or
be associated with its expression level, some genes being trans-
activated only when ELF3 is overexpressed. In any case, ELF3 is
implicated in the development of periampullary tumors, and its
exact functional role during periampullary tumor development
will need to be investigated further.EXPERIMENTAL PROCEDURES
Clinical Data
A total of 160 tumors (98 AMPAC, 44 CAC, and 18 DUOAC) were collected by
the different groups participating in this study: Australian Pancreatic Cancer
Genome Initiative (APGI), Baylor College of Medicine Elkins Pancreatic Center
(BCM) as a member of The Cancer Research Banking, MD Anderson Cancer
Center (MDA), and Technical University of Dresden (TUD). Ethical approval
was obtained from each of these institution’s research ethic boards. All
patients underwent surgical pancreatoduodenectomy with curative intent
without known residual disease. Clinical data variables including race, sex,
age, familial history, operative procedure, pathological findings, and survival
from the date of initial surgery to the date of death or last follow up are pre-
sented in Table S1A.Tumor Classification
A section of the tumor was fixed in formaldehyde and embedded in paraffin
(FFPE). H&E-stained and immunohistochemistry slides from the FFPE tissue
were examined by the pathologists from the original site of collection to
confirm diagnosis of the specific tumor section and to grade expression of
subtype markers. All slides were then centrally reviewed by a single patholo-
gist (A.G.) who was blinded to all clinical, molecular, and pathological data
at the time of review and scoring. The distinction between pancreatic, biliary,
ampullary or intestinal carcinomawas based on the anatomical site fromwhich
the carcinoma was thought to arise using the guidelines recommended in the
AJCC seventh edition 2009 staging manual (Edge et al., 2009).
Histology and Morphology
Tumors were classified as pancreatobiliary, intestinal, or mixed morphological
subtype based on the cellular morphology. A morphology similar to colorectal
adenocarcinoma (tall often pseudostratified columnar epithelium with oval
nuclei forming elongated glands) was defined as intestinal type. Morphology
similar to pancreatobiliary carcinoma (small solid nest of cells with rounded
nuclei surrounded by desmoplastic stroma and forming simple or branching
rounded glands) was defined as pancreatobiliary type. Mixed histological
types contained a mixture of both intestinal and pancreatobiliary types with
80% or less of the cells with either morphology. Grade of differentiation was
also noted aswell as presence of adenoma, signet-ring cells, ormucinous cells
(Table S1B).dUHRF2 expression. Human Omni 2.5 SNP array results were analyzed in IGV
tions are in red. Gene expressionwas analyzed by dividing the samples into two
t indicates the tumor type (pink, AMPAC; purple, CAC; and orange, DUOAC).
ell Reports 14, 907–919, February 2, 2016 ª2016 The Authors 915
Immunohistochemistry Staining
FFPE sections were stained with antibodies against MUC1 and CDX2 (see
Supplemental Experimental Procedures). This two-antibody panel has previ-
ously been validated by our group to predict prognosis in ampullary carcinoma
(Chang et al., 2013), and the methods we used were the same as employed in
that study. Briefly, expression was evaluated by estimating the percentage of
positively stained carcinoma cells and the intensity of the staining (0 absent, 1+
weak, 2+, 3+ strong). H scores were calculated for bothmarkers bymultiplying
the percentage of stained cells by the intensity of the staining. The ratio of the
CDX2/MUC1 H score defined the subtypes: a ratio of 2 and above and smaller
than 0.5 were considered intestinal and pancreatobiliary, respectively. Inter-
mediate values were associated to a mixed subtype (Table S1B).
Nucleic Acid Isolation
Samples were retrieved and had full face sectioning performed in OCT embed-
ding media to verify the presence of carcinoma in the sample to be sequenced
and to estimate the percentage of malignant epithelial nuclei in the sample
relative to stromal nuclei. Macrodissection was performed if possible to excise
areas of non-malignant tissue. DNA and RNA extraction was performed at the
center of collection following their own protocol with all samples being tracked
using unique identifiers though out the process (see Supplemental Methods).
DNAwas shipped and quantified at BCM-Human Genome Sequencing Center
(HGSC) using the PicoGreen DNA Assay.
SNP Array Assays
SNP arrays were processed at the HGSC for each sample using the Illumina
Infinium LCG Assay according to the manufacturer’s guidelines. Specifically,
assays were performed with Human Omni2.5-8 BeadChips (Illumina, catalog
no.WG-311-2513), interrogating 2.5million SNP loci with aMAF detection limit
of 1% (see Supplemental Experimental Procedures). SNP calls were collected
using Illumina’s GenomeStudio software (version 2011.1) in which standard
SNP clustering and genotyping were performed with the default settings rec-
ommended by the manufacturer. Data from samples that met a minimum SNP
call rate of 0.9 were considered passing and were included in subsequent an-
alyses. Results were analyzed on Nexus (BioDiscovery).
Sequencing
Library preparation, whole (Bainbridge et al., 2011) and targeted exome cap-
ture, and regular and ultra-deep sequencing on HiSeq 2000 platform are
detailed in Supplemental Experimental Procedures. In brief, 152 samples
were whole-exome sequenced and their mutations validated with a custom
design targeted exome capture. The targeted capture consisted of a panel
of 71 genes covering 0.25 Mb, and the probes were designed by Nimblegen
(genes are listed in Supplemental Experimental Procedures). These genes
were selected on the basis they were significantly mutated and/or had
high impact in the development of AMPAC, PDAC, DUOAC, CAC, and other
pancreatic tumor types. The selective targeted capture was also used in dis-
covery on eight samples received at a later date (six samples) or of low purity
(two samples with <10% tumor). The mutations identified with the targeted
capture were validated with ultra-deep (single-molecule reconstruction)
sequencing.
Data Analysis
Primary Data Analysis
Initial sequence analysis was performed using the HGSC Mercury analysis
pipeline (https://www.hgsc.bcm.edu/software/mercury). First, the primary
analysis software on the instrument produces .bcl files that are transferred
off-instrument into the HGSC analysis infrastructure by the HiSeq Real-time
Analysis module. Once the run is complete and all .bcl files are transferred,
Mercury runs the vendor’s primary analysis software (CASAVA), which demul-
tiplexes pooled samples and generates sequence reads and base-call
confidence values (qualities). The next step is the mapping of reads to the
GRCh37 Human reference genome (http://www.ncbi.nlm.nih.gov/projects/
genome/assembly/grc/human/) using the Burrows-Wheeler aligner (Li and
Durbin, 2009) (BWA; http://bio-bwa.sourceforge.net/) and producing a BAM
(Li et al., 2009) (binary alignment/map) file. The third step involves quality reca-
libration (using GATK; DePristo et al., 2011; https://www.broadinstitute.org/916 Cell Reports 14, 907–919, February 2, 2016 ª2016 The Authorsgatk/) and, where necessary, the merging of separate sequence-event
BAMs into a single sample-level BAM. BAM sorting, duplicate-read marking,
and realignment to improve in/del discovery all occur at this step.
Cancer Data Analysis
Primary BAM files were separately run through Atlas-SNP (Shen et al., 2010),
Atlas-Indel, and PInDel (Ye et al., 2009). Data were aggregated for each tumor/
normal pair, and variants were cross-checked for each tissue pair. Variant
annotation was performed using Annovar (Wang et al., 2010), COSMIC (Forbes
et al., 2011), and dbSNP (Sherry et al., 2001). Variant filtering was performed to
remove low-quality variants. Cohort-level data processing was performed to
remove additional false somatic calls by filtering against a cohort of normal
tissues.
Ultra-deep Sequencing Analysis
Duplicate reads were aggregated and consensus variants were defined as the
variant being present in 90% of the reads contributing to both halves of the
duplex molecule. Subsequent filtering was employed to remove variants in
which there was either mapping error (tested using BLAST) or sequence error
non-consensus block rate of 50% (Altschul et al., 1990). Variants detected in
this way were annotated using ANNOVAR, COSMIC, and dbSNP annotations
(Forbes et al., 2011; Sherry et al., 2001; Wang et al., 2010).
Mutational Signature
Mutation signatureswere generated froma set of over 6,000 somaticmutations
across a range of cancer types using non-smooth non-negative matrix factor-
ization (nsNMF) (K.R.C., unpublished data; Pascual-Montano et al., 2006). The
solution resulted in 21distinctmutational signatures, similar to those previously
reported (Alexandrov et al., 2013; Gaujoux and Seoighe, 2010), many of which
could be correlated with previously published mutational modes, including
APOBEC, UV radiation exposure, POLE hypermutation (Lawrence et al.,
2013), and CpG island mutation. Mutations for this cohort where compared
against the solved NMF to generate a mutational decomposition for each of
the tumor samples. Samples were aggregated and compared using hierarchi-
cal clustering and other correlative statistics to clinical covariates.
Tumor Purity and Normalization Mutation Rate
Tumor purity was estimated using ASCAT and the tumor variant allelic fraction
of driver genes. The average of both analyses was plotted against the number
of mutations in each tumor, and the slope value was used to approximate the
number of mutations that would have been identified in 100% tumor cellularity
(Figure S1A).
Significantly Altered Genes
Several approaches were taken to dissect genes and pathways which
were mutated more often than by chance in this dataset. We used the final
MAF file (Tables S6A and 6B) to calculate significantly mutated genes using
MutSig-CV and an inactivation bias test (Lawrence et al., 2013; Totoki et al.,
2014).
Microsatellite Instability Coefficient
For details, see Supplemental Experimental Procedures.
Multivariable Cox Analysis
Cox proportional hazards analysis was performed using the survival (Ther-
neau, 2000) package in R (R Development Core Team, 2008). We included
age at diagnosis, gender, stage, grade, tumor type, histologic subtype (IHC),
and mutation status (WNT, TGFB, TP53, KRAS, PI3K, and chromatin remodel-
ing) in the multivariate Cox analysis. Country of origin and ethnicity were not
included as covariates since they had no associated effect with survival.
RNA-Seq
Total RNA was prepared using the AllPrep RNA/DNA isolation kit (QIAGEN).
RNA integrity was confirmed (RIN > 7.0) on a Bioanalyzer (Agilent). RNA-seq
libraries were prepared using the TruSeq Stranded total RNA LT library kit
(Illumina) following the manufacturer’s instructions. 100-base-pair-end
sequencing was then performed to a minimum depth of 50 million reads of
each sample on an Illumina HiSeq2000 sequencer.
Transcript Expression Analysis
Gene Expression of theWNT Pathway
The profiles in the RNA-seq dataset were quantile normalized, and log-trans-
formed expression values were then centered to SDs from the median across
sample profiles. Tumors were split into two groups (those withWNT canonical
pathway mutations and those without such mutations) and were scored for
relative activity in theWNT pathway. The gene signature score within each tu-
mor profile was defined as the average of the centered values for the WNT
signature genes.
Fusion Analysis
The deFuse software version 0.6.1 (McPherson et al., 2011) with default set-
tings was used to detect fusion genes. The deFuse results were further filtered
by removing identified read through fusions, selecting coding regions, select-
ing in-frame (open reading frame) genes and selecting samples with a deFuse
confidence score of >80%. This filtering resulted in a list of candidate fusion
genes. To characterize these candidate fusion genes, we took each spanning
junction read and using the BLAT tool in UCSC genome browser examined
where the reads mapped. The fusions that mapped with 100% identity to
each part of the identified fusion (gene1 or gene2) were selected for further
analysis. This filter removed genes that mapped to multiple locations. Next,
each RNA BAM from candidate fusion genes was examined in IGV, looking
for stacked soft clipped reads, changes in coverage, at the identified fusion
breakpoints. The sequence of each soft clipped read was brought into the
UCSC genome browser and mapped using BLAT. Only fusions that had reads
that matched (100%) the identified fusion genes were considered further.
ACCESSION NUMBERS
The accession number for the sequence data reported in this paper is dbGAP:
PRJNA280134.
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